Erasca (ERAS) News Today $1.23 -0.06 (-4.30%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Suvretta Capital Management LLC Has $30.91 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS)Suvretta Capital Management LLC lowered its position in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) by 10.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,315,004 shares of the company's stock after selling 1,453,035 sharesMay 19 at 7:38 AM | marketbeat.comHC Wainwright Analysts Lift Earnings Estimates for ErascaMay 18 at 1:55 AM | americanbankingnews.comProsight Management LP Trims Holdings in Erasca, Inc. (NASDAQ:ERAS)Prosight Management LP trimmed its position in Erasca, Inc. (NASDAQ:ERAS - Free Report) by 52.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 947,110 shares of the company's stock after selling 1,036,900 sMay 17, 2025 | marketbeat.com5,136,795 Shares in Erasca, Inc. (NASDAQ:ERAS) Bought by Octagon Capital Advisors LPOctagon Capital Advisors LP bought a new stake in Erasca, Inc. (NASDAQ:ERAS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,136,795 shares of the company's stock, valued at approximMay 15, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS)Dimensional Fund Advisors LP increased its stake in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) by 74.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,111,986 shares of the company's stock after buyMay 15, 2025 | marketbeat.comErasca Reports First Quarter 2025 Business Updates and Financial ResultsMay 13, 2025 | globenewswire.comErasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash RunwayMay 13, 2025 | globenewswire.comErasca (ERAS) Projected to Post Earnings on WednesdayMay 12, 2025 | americanbankingnews.comErasca (ERAS) to Release Earnings on WednesdayErasca (NASDAQ:ERAS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-erasca-inc-stock/)May 9, 2025 | marketbeat.comErasca to Present at the Bank of America Securities Health Care ConferenceMay 7, 2025 | globenewswire.comErasca (NASDAQ:ERAS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $6.00 target price on shares of Erasca in a research report on Wednesday.May 2, 2025 | marketbeat.comErasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual MeetingApril 29, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)April 29, 2025 | theglobeandmail.comErasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Buy" from BrokeragesShares of Erasca, Inc. (NASDAQ:ERAS - Get Free Report) have received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among brokApril 28, 2025 | marketbeat.comMarshall Wace LLP Sells 1,000,700 Shares of Erasca, Inc. (NASDAQ:ERAS)Marshall Wace LLP cut its holdings in Erasca, Inc. (NASDAQ:ERAS - Free Report) by 33.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,027,027 shares of the company's stock after selling 1,000,700 shares during theApril 27, 2025 | marketbeat.comWalleye Capital LLC Has $348,000 Stock Position in Erasca, Inc. (NASDAQ:ERAS)Walleye Capital LLC lessened its holdings in Erasca, Inc. (NASDAQ:ERAS - Free Report) by 85.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 138,708 shares of the company's stock after selling 810,849 shares during the quarteApril 27, 2025 | marketbeat.comErasca, Inc.: Carving A Different Niche In RAS SignalingApril 25, 2025 | seekingalpha.comErasca, Inc.: Carving A Different Niche In RAS SignalingApril 25, 2025 | seekingalpha.comSilverarc Capital Management LLC Grows Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)Silverarc Capital Management LLC lifted its position in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,543,901 shares of the company's stock afterApril 24, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Short Interest Down 17.8% in MarchErasca, Inc. (NASDAQ:ERAS - Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 27,220,000 shares, a drop of 17.8% from the March 15th total of 33,100,000 shares. Currently, 16.6% of the company's shares are sold short. Based on an average daily trading volume, of 1,630,000 shares, the days-to-cover ratio is presently 16.7 days.April 22, 2025 | marketbeat.comJPMorgan Chase & Co. Lowers Holdings in Erasca, Inc. (NASDAQ:ERAS)JPMorgan Chase & Co. lowered its position in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) by 27.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,474,585 shares of the company's stock after selling 5April 22, 2025 | marketbeat.comIs Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 17, 2025 | msn.comWellington Management Group LLP Acquires New Stake in Erasca, Inc. (NASDAQ:ERAS)Wellington Management Group LLP bought a new position in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 465,672 shares of the company's stock, vApril 15, 2025 | marketbeat.comVanguard Group Inc. Sells 614,840 Shares of Erasca, Inc. (NASDAQ:ERAS)Vanguard Group Inc. lowered its holdings in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) by 4.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,673,900 shares of the company's stock after sellingApril 15, 2025 | marketbeat.comErasca Slides As Insider Purchases Lose Another US$84kApril 8, 2025 | finance.yahoo.comErasca, Inc. (NASDAQ:ERAS) Receives Consensus Recommendation of "Buy" from AnalystsShares of Erasca, Inc. (NASDAQ:ERAS - Get Free Report) have received an average recommendation of "Buy" from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price amongApril 2, 2025 | marketbeat.comIPG Investment Advisors LLC Acquires Shares of 169,978 Erasca, Inc. (NASDAQ:ERAS)IPG Investment Advisors LLC bought a new position in shares of Erasca, Inc. (NASDAQ:ERAS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 169,978 shares of the company's stock, valued at approxiMarch 31, 2025 | marketbeat.comErasca (ERAS) Gets a Buy from J.P. MorganMarch 30, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Erasca (ERAS)March 27, 2025 | markets.businessinsider.comErasca (NASDAQ:ERAS) Now Covered by Raymond JamesRaymond James began coverage on Erasca in a report on Wednesday. They issued an "outperform" rating and a $5.00 price objective for the company.March 27, 2025 | marketbeat.comRaymond James Initiates Coverage of Erasca (ERAS) with Outperform RecommendationMarch 26, 2025 | msn.comErasca Announces Three Poster Presentations at the 2025 AACR Annual MeetingMarch 25, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for Erasca FY2029 Earnings?Erasca, Inc. (NASDAQ:ERAS - Free Report) - Analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Erasca in a report released on Friday, March 21st. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.06) per share for the year. HC Wainwright currently haMarch 24, 2025 | marketbeat.comThe Goldman Sachs Group Issues Pessimistic Forecast for Erasca (NASDAQ:ERAS) Stock PriceThe Goldman Sachs Group dropped their price objective on shares of Erasca from $3.50 to $3.00 and set a "buy" rating on the stock in a research note on Friday.March 22, 2025 | marketbeat.comErasca's (ERAS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $6.00 target price on shares of Erasca in a research note on Friday.March 22, 2025 | marketbeat.comErasca (NASDAQ:ERAS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPSErasca (NASDAQ:ERAS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01.March 21, 2025 | marketbeat.comErasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial ResultsMarch 21, 2025 | finanznachrichten.deErasca reports Q4 EPS (11c), consensus (13c)March 21, 2025 | markets.businessinsider.comErasca, Inc. Reports 2024 Financial and Strategic ProgressMarch 21, 2025 | tipranks.comErasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial ResultsMarch 20, 2025 | globenewswire.comErasca (ERAS) Expected to Announce Earnings on WednesdayErasca (NASDAQ:ERAS) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comErasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Buy" from AnalystsErasca, Inc. (NASDAQ:ERAS - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stockMarch 8, 2025 | marketbeat.comMorgan Stanley Reaffirms "Overweight" Rating for Erasca (NASDAQ:ERAS)Morgan Stanley reissued an "overweight" rating and set a $4.00 price objective on shares of Erasca in a report on Friday.March 8, 2025 | marketbeat.comErasca assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comErasca (NASDAQ:ERAS) Reaches New 52-Week Low - Here's What HappenedErasca (NASDAQ:ERAS) Sets New 1-Year Low - Here's What HappenedFebruary 7, 2025 | marketbeat.comErasca (NASDAQ:ERAS) Stock Price Down 6.1% - Time to Sell?Erasca (NASDAQ:ERAS) Trading Down 6.1% - Time to Sell?February 3, 2025 | marketbeat.comErasca (NASDAQ:ERAS) Shares Up 6.6% - Here's What HappenedErasca (NASDAQ:ERAS) Trading Up 6.6% - Here's WhyJanuary 31, 2025 | marketbeat.comErasca to Present at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 31, 2025 | globenewswire.comErasca: Future 'Streamlined' But Still UncertainJanuary 28, 2025 | seekingalpha.comErasca's Naporafenib Is Shaping Up Nicely For NRASm MelanomaJanuary 27, 2025 | seekingalpha.com Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Media Mentions By Week ERAS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERAS News Sentiment▼1.000.65▲Average Medical News Sentiment ERAS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERAS Articles This Week▼82▲ERAS Articles Average Week Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Indivior News Edgewise Therapeutics News Janux Therapeutics News Evotec News Immunocore News Mesoblast News Adaptive Biotechnologies News Vera Therapeutics News Dyne Therapeutics News Structure Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERAS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ERAS Stock Free ERAS Stock Alerts